Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks liver risks of livmarli in kids with rare diseases

NCT ID NCT07293897

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 28 times

Summary

This study looks at how often liver problems happen in Japanese children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli. Researchers will use a national database to track side effects in about 50 patients. The goal is to better understand the safety of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Takeda selected site

    RECRUITING

    Tokyo, Tokyo, Japan

Conditions

Explore the condition pages connected to this study.